Citigroup Initiates Coverage On BioMarin Pharmaceutical with Buy Rating, Announces Price Target of $75
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Eric Joseph initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy rating and announces Price Target of $75.
Citigroup analyst Eric Joseph initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy rating and announces Price Target of $75.